Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer (TAYLOR-003)

NCT07616427 is registered in ClinicalTrials.gov with Second Affiliated Hospital, Zhejiang University, School of Medicine as lead sponsor.

NCT NCT07616427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07616427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer (TAYLOR-003)
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase
Phase 2
Overall status
Recruiting
Start date
May 20, 2026
Completion date
May 20, 2033
Enrollment
100 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hr+/her2+ early breast cancer